Protocol Ledger

NCT05973864 · Phase II · RECRUITING

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Interventional Phase II clinical trial protocol NCT05973864 sponsored by UNICANCER in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-11 Enrollment: 220 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05973864
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)220 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05973864
Protocol FieldVerified Registry Value
NCT IdentifierNCT05973864
Consolidated Lead SponsorUNICANCER
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment220 participants (ESTIMATED)
Registered Start Date2025-03-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05973864
Hospital Research SiteLocationSite Profile
Institut Sainte CatherineAvignon, FranceOpen Hospital Dossier ->
Centre François BaclesseCaen, FranceOpen Hospital Dossier ->
Centre Georges-François LeclercDijon, FranceOpen Hospital Dossier ->
Centre Oscar LambretLille, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI